This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech
2026-05-15T04:34:27.272Z